CTEPH News

March 6, 2019March 12, 2019

Transition from PDE5i to Adempas Without Washout Period Deemed Safe

Transition from phosphodiesterase-5 inhibitors (PDE5i) — such as United Therapeutics’ Adcirca (taladafil) and Pfizer‘s Revatio (sildenafil) — to Bayer‘s Adempas (riociguat), a soluble guanylate cyclase (sGC) stimulator, without a washout period ... Read more

February 21, 2019February 27, 2019

Higher Levels of 2 Autoantibodies Could Help Diagnose CTEPH and PAH, Study Suggests

CTEPH News, News, PAH News

Patients with chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) have higher serum levels of antibodies against the EDX2 and PHAX proteins, according to research which suggests ... Read more

February 20, 2019February 25, 2019

Balloon Pulmonary Angioplasty Can Shorten CTEPH Patients’ Hospital Stays, Study Reports

CTEPH News, News

Greater experience in balloon pulmonary angioplasty (BPA) enables shorter hospital stays for patients with chronic thromboembolic pulmonary hypertension (CTEPH), reduces use of intensive care, and lowers medical costs while maintaining the ... Read more

January 21, 2019January 25, 2019

Actelion Needs Further Studies on Opsumit Treatment for Inoperable CTEPH, US FDA Says

CTEPH News, News

Actelion Pharmaceuticals has received a complete response letter from the U.S. Food and Drug Administration (FDA) specifying that the company needs to conduct further studies and obtain more data in order ... Read more

January 11, 2019January 14, 2019

Long-term Adempas Treatment May Reverse Right Heart Deficits in Patients with PAH, CTEPH, Study Finds

CTEPH News, News, PAH News

Long-term treatment with Adempas (riociguat) can reduce right heart size and improve the heart’s pumping function in patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), ... Read more

January 3, 2019January 11, 2019

Obstructive Sleep Apnea Affects Cardiac Function of CTEPH Patients

CTEPH News, News

Worse measures of blood flow, arterial oxygenation, and cardiac function may underlie the poor clinical condition of chronic thromboembolic pulmonary hypertension (CTEPH) patients who also have obstructive sleep apnea ... Read more

December 6, 2018December 7, 2018

CTEPH Software Receives FDA’s Breakthrough Device Designation

CTEPH News

The U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation to software being developed by Bayer and Merck — known as MSD outside the U.S. and Canada — to ... Read more

October 22, 2018October 23, 2018

New Procedure Successfully Treats CTEPH Patient at Northwestern Hospital in Illinois

CTEPH News, News

A new procedure, performed at Northwestern Memorial Hospital in Illinois, successfully treated a patient with pulmonary hypertension (PH) caused by blood clots formed in the lung vessels, a condition referred ... Read more

October 3, 2018October 15, 2018

Inspiratory Muscle Weakness Aggravates Shortness of Breath in CTEPH Patients, Study Shows

CTEPH News, News

Inspiratory muscle weakness aggravates shortness of breath caused by exertion and lung function capacity in patients with chronic thromboembolic pulmonary hypertension, a study has found. The study, “Inspiratory muscle weakness ... Read more

September 5, 2018September 6, 2018

Actelion Seeks Expanded Approval of Opsumit for Treatment of CTEPH in Europe

CTEPH News, News

Actelion Pharmaceuticals has filed a request with the European Medicines Agency for the expanded approval of Opsumit (macitentan) as a treatment for adults with moderate to severe inoperable chronic ... Read more

Pin It on Pinterest